Suppr超能文献

基于肺癌 TNM 系统的肺类癌改良分期系统。

Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system.

机构信息

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11566, Egypt.

出版信息

Clin Transl Oncol. 2018 May;20(5):670-677. doi: 10.1007/s12094-017-1759-2. Epub 2017 Oct 11.

Abstract

BACKGROUND

Pulmonary carcinoids are being staged along the lines of lung cancer American Joint Committee on Cancer (AJCC) staging system. The current study evaluated the prognostic value of a modified staging system for patients with pulmonary carcinoid.

PATIENTS AND METHODS

Surveillance, Epidemiology and End Results (SEER) database (2004-2014) was searched through SEER*Stat program. Through recursive partitioning analysis and subsequent decision tree formation, suggested stages were constructed. Overall survival analyses were performed through Kaplan-Meier analysis. The cancer-specific Cox regression hazard (adjusted for age, gender, race, sub-site and surgery) was calculated and pairwise comparisons of hazard ratios were conducted.

RESULTS

A total of 6395 pulmonary carcinoid patients were recruited in the period from 2004-2014. Pairwise hazard ratio comparisons among different AJCC 8th stages were conducted and all comparisons were non-significant except for stage IIB vs. stage IIIA and stage IIIA vs. stage IIIB. Pairwise hazard ratio comparisons among different modified staging system stages were conducted and all comparisons were significant except for stage III vs. stage IV. C-statistic (using death from pulmonary carcinoid as the dependent variable) for AJCC 8th staging system was: 0.794 (SE 0.013; 95% CI 0.769-0.818); for AJCC 7th staging system was: 0.789 (SE 0.013; 95% CI 0.764-0.815), while c-statistic for the modified staging system was: 0.802 (SE 0.012; 95% CI 0.778-0.827).

CONCLUSION

The proposed modified staging system provided a simpler yet prognostically more relevant classification of pulmonary carcinoids compared to AJCC staging systems (both 7th and 8th editions).

摘要

背景

类癌肿瘤的分期沿用肺癌美国癌症联合委员会(AJCC)分期系统。本研究评估了改良分期系统对类癌肿瘤患者的预后价值。

方法

通过 SEER*Stat 程序检索监测、流行病学和最终结果(SEER)数据库(2004-2014 年)。通过递归分区分析和随后的决策树形成,构建建议的分期。通过 Kaplan-Meier 分析进行总生存分析。计算癌症特异性 Cox 回归风险(调整年龄、性别、种族、亚部位和手术),并进行风险比的两两比较。

结果

2004-2014 年期间共纳入 6395 例类癌肿瘤患者。对不同 AJCC 第 8 期之间的风险比进行了两两比较,除了 IIB 期与 IIIA 期和 IIIA 期与 IIIB 期之外,所有比较均无统计学意义。对不同改良分期系统分期之间的风险比进行了两两比较,除了 III 期与 IV 期之外,所有比较均有统计学意义。AJCC 第 8 分期系统的 C 统计量(以类癌肿瘤死亡为因变量)为:0.794(SE 0.013;95%CI 0.769-0.818);AJCC 第 7 分期系统为:0.789(SE 0.013;95%CI 0.764-0.815),而改良分期系统的 C 统计量为:0.802(SE 0.012;95%CI 0.778-0.827)。

结论

与 AJCC 分期系统(第 7 版和第 8 版)相比,提出的改良分期系统提供了一种更简单但预后相关性更强的类癌肿瘤分类方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验